Scholarlink

<p>Multiple myeloma, a hematopoietic malignancy of terminally differentiated B cells, is the second most common hematological malignancy after leukemia. While patients have benefited from numerous advances in treatment in recent years resulting in significant increases to average survival time following diagnosis, myeloma remains incurable and relapse is common. To help identify novel therapeutic agents with efficacy against the disease and to search for biomarkers associated with differential response to treatment, a large-scale pharmacological screen was performed with 1,912 small molecule compounds tested at 11 doses for 47 human myeloma cell lines (HMCL). Raw and processed versions of the drug screen dataset are provided, as well as supportive information including drug and cell line metadata and high-level characterization of the most salient features of each. The dataset is publicly available at Zenodo and the workflow code used for data processing and generation of supporting figures and tables are available on GitHub.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Large-scale human myeloma cell line small molecule compound screen dataset

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年4月19日

查看全文
  • V. Keith Hughitt,
  • John K. Simmons,
  • Sayeh Gorjifard,
  • Aleksandra Michalowski,
  • Kelli Wilson,
  • Xiaohu Zhang,
  • Paul Shinn,
  • Carleen Klumpp-Thomas,
  • Crystal McKnight,
  • Zina Itkin,
  • Lu Chen,
  • Sam Michael,
  • Jonathan Keats,
  • Craig Thomas,
  • Beverly A. Mock

摘要

Multiple myeloma, a hematopoietic malignancy of terminally differentiated B cells, is the second most common hematological malignancy after leukemia. While patients have benefited from numerous advances in treatment in recent years resulting in significant increases to average survival time following diagnosis, myeloma remains incurable and relapse is common. To help identify novel therapeutic agents with efficacy against the disease and to search for biomarkers associated with differential response to treatment, a large-scale pharmacological screen was performed with 1,912 small molecule compounds tested at 11 doses for 47 human myeloma cell lines (HMCL). Raw and processed versions of the drug screen dataset are provided, as well as supportive information including drug and cell line metadata and high-level characterization of the most salient features of each. The dataset is publicly available at Zenodo and the workflow code used for data processing and generation of supporting figures and tables are available on GitHub.